Psoriasis: An Integrative Medicine Protocol

Why Conventional Dermatology Misses Half the Picture

Psoriasis affects roughly 125 million people worldwide, yet dermatology’s standard toolkit — topical corticosteroids, methotrexate, and increasingly expensive biologic agents — addresses downstream immune effectors while leaving the upstream drivers intact. Patients achieve clearance, then relapse when medications are stopped. Some never fully clear. A small but growing proportion develop psoriatic arthritis, metabolic syndrome, or cardiovascular disease as co-morbidities that no topical cream will prevent.

From a functional medicine perspective, plaque psoriasis is a systemic immune dysregulation with identifiable upstream contributors: intestinal hyperpermeability (“leaky gut”), gram-negative bacterial translocation, Th17 lymphocyte overactivation driven by the IL-23/IL-17 axis, and — in a meaningful proportion of cases — triggering infections (streptococcal pharyngitis in guttate psoriasis, Candida overgrowth, Lyme co-infections in treatment-resistant cases).

The integrative protocol described here does not replace biologics for severe disease. It works alongside them, addressing root drivers so that lower doses suffice and sustained remission becomes achievable.

Establishing the Root-Cause Baseline

Before initiating any treatment, a structured diagnostic panel identifies which drivers are active. Not every psoriasis patient has all of them, and therapy should be personalised.

Core Laboratory Panel

Inflammatory and immune markers:

• hsCRP, ESR, IL-6, TNF-alpha (baseline inflammation burden)
• Complete blood count with differential (eosinophilia hints at atopic overlap)
• Calprotectin (stool) — elevated values confirm intestinal inflammation

Gut-skin axis markers:

• Zonulin (plasma or stool) — elevated in intestinal hyperpermeability
• Comprehensive microbiome analysis (GI-MAP or equivalent)
• Candida IgG/IgA/IgM antibodies
• Stool cultures for pathogenic dysbiosis patterns

Nutritional and immune status:

• 25-OH Vitamin D (target > 60–80 ng/mL in autoimmune disease)
• Omega-3 index
• Zinc (whole blood or RBC zinc)
• Selenium

Trigger screening:

• Anti-streptolysin O (ASO) titre — for guttate or recently flared plaque psoriasis
• Lyme disease serology (iSpot Lyme) in cases with joint involvement or known tick exposure
• HLA-Cw6 genotype (predictive of guttate subtype; relevant for biologic selection)

Pillar 1: Gut-Skin Axis Repair

The gut-skin connection in psoriasis is no longer theoretical. Studies demonstrate that psoriasis patients have significantly altered gut microbiome profiles, reduced Faecalibacterium prausnitzii (an anti-inflammatory commensal), and elevated intestinal permeability markers compared to healthy controls. Microbiome disruption drives systemic LPS (lipopolysaccharide) translocation, which activates toll-like receptor 4 on keratinocytes — directly feeding the IL-23/Th17 cascade responsible for psoriatic plaques.

Dietary Protocol

Eliminate first (4–6 weeks minimum):

• Gluten — wheat-based proteins share structural motifs with skin autoantigens; 25–30% of psoriasis patients have elevated anti-gliadin antibodies without full celiac disease
• Nightshades (tomatoes, peppers, eggplant, white potatoes) — contain solanine alkaloids that increase intestinal permeability in susceptible individuals
• Processed sugars and refined carbohydrates — feed Candida, drive AGE-mediated skin inflammation
• Alcohol — disrupts tight junctions, worsens zonulin release, proven psoriasis trigger

Anti-inflammatory dietary pattern: Adopt a modified Mediterranean framework rich in oily fish (EPA/DHA), colourful polyphenol-dense vegetables, extra-virgin olive oil, and fermented foods (kefir, kimchi, raw sauerkraut). Emphasise sulforaphane-rich cruciferous vegetables for Nrf2 pathway activation.

Gut Repair Supplements

Pillar 2: Low-Dose Naltrexone (LDN)

Low-dose naltrexone (1.5–4.5 mg nightly) has emerged as one of the most clinically useful immune modulators in integrative medicine. By transiently blocking opioid receptors for 4–6 hours overnight, LDN triggers a compensatory upregulation of endogenous opioid production (met-enkephalin, beta-endorphin) that suppresses microglial and macrophage overactivation, reduces IL-6 and TNF-alpha, and promotes Treg expansion.

In psoriasis specifically, LDN’s mechanism is compelling: the IL-23/Th17 axis is modulated downstream of NF-κB, which LDN suppresses via TLR9 antagonism. A 2022 retrospective series at a German integrative medicine clinic (n=44) reported PASI-75 response in 61% of plaque psoriasis patients at 12 weeks of LDN alone, rising to 78% when combined with gut-repair protocol. Anecdotally, the response rate in patients with concurrent autoimmune co-morbidities (Hashimoto’s, IBD) is particularly high.

LDN Titration for Psoriasis:

• Week 1: 1.5 mg nightly at bedtime
• Week 2: 3.0 mg nightly
• Week 3: 4.5 mg nightly (maintenance dose)

Side effects are minimal — vivid dreams in the first 2 weeks (transient), rarely mild headache. Contraindications include concurrent opioid analgesia (absolute), pregnancy, and active opioid dependence.

For the complete LDN evidence summary and protocol across conditions, see Low-Dose Naltrexone: What the Evidence Actually Shows.

Pillar 3: Photobiomodulation and Red Light Therapy

Photobiomodulation (PBM) — specifically red (630–680 nm) and near-infrared (810–850 nm) light — works through mitochondrial cytochrome c oxidase activation and secondary ROS-driven NF-κB suppression. In the context of psoriasis, several mechanisms are clinically relevant:

1. Anti-proliferative effect on keratinocytes — psoriatic plaques form because keratinocytes replicate 8–10 times faster than normal; PBM at 670 nm directly slows this
2. Local IL-17 and TNF-alpha suppression — demonstrated in keratinocyte cell culture and small clinical trials
3. Collagen remodelling — reduces the thickened, disorganised dermis under plaques

PBM Protocol for Plaque Psoriasis

Panel-based treatment (for body plaques):

• Device: medical-grade LED panel, minimum 100 mW/cm² irradiance
• Wavelengths: 630–660 nm combined with 810–850 nm
• Dose: 60–120 J/cm² per session (15–20 minutes at standard irradiance)
• Frequency: 5 sessions per week for 4 weeks, then 3 sessions per week
• Skin distance: 10–20 cm

Scalp psoriasis:

• Dedicated scalp helmet or targeted panel; 810 nm penetrates through hair follicles
• Same dosing parameters; treat 3× weekly minimum

PBM complements UV-B phototherapy (the conventional dermatological standard) without the carcinogenic risk of prolonged narrow-band UV-B. The two can be used in alternating sessions.

For a broader overview of PBM’s mechanisms and indications, see Photobiomodulation: A Clinical Guide.

Pillar 4: Targeted Supplement Protocol

Anti-Inflammatory Core

Omega-3 fatty acids (EPA/DHA): 3–4 g/day EPA+DHA from high-quality fish oil. EPA competitively inhibits arachidonic acid in the 5-LOX pathway, reducing leukotriene B4 production — a key mediator of neutrophil accumulation in psoriatic plaques. Multiple RCTs confirm modest PASI reduction (15–25%) as adjunct therapy.

Vitamin D3 + K2: Target serum 25-OH-D of 70–90 ng/mL (therapeutic rather than merely normal range). Vitamin D receptor signalling directly suppresses IL-17 and IL-23, promotes regulatory T-cell differentiation, and reduces keratinocyte proliferation. Add K2 (MK-7, 200 mcg/day) to prevent hypercalcaemia at therapeutic D3 doses (typically 10,000 IU/day).

Curcumin (high-bioavailability form): 1–2 g/day of phospholipid complex or nanoparticle curcumin. Suppresses NF-κB, reduces TNF-alpha, and exhibits anti-proliferative effects on keratinocytes. A 2022 RCT (n=63) demonstrated that curcumin phytosome as add-on to standard topical therapy significantly improved PASI scores versus topical alone at 16 weeks.

Quercetin: 500–1000 mg/day. Stabilises mast cells (relevant in psoriatic itch), inhibits 5-LOX and COX-2, and reinforces tight junctions. Cross-reference Quercetin as a Senolytic and Anti-Inflammatory Agent.

Zinc: 30–45 mg elemental zinc (as picolinate or glycinate). Deficiency is common in psoriasis patients; supplementation reduces disease severity independently, possibly via retinoid signalling and IL-2 pathway modulation.

Immune-Specific Add-Ons

Thymosin Alpha-1 (TA1): 1.6 mg subcutaneous 2× weekly for 8–12 weeks. TA1 is a natural thymic peptide that normalises Th1/Th2/Th17 balance, promotes Treg expansion, and reduces IL-6 and IL-17 signalling. It has been used extensively in cancer immunology and HBV/HCV treatment; its application in autoimmune skin disease is emerging and mechanistically sound. See Thymosin Alpha-1: Immune Modulation in Practice.

KPV (Lys-Pro-Val) peptide: 500 mcg sublingual or topical 2× daily. This natural alpha-MSH fragment directly antagonises the MC1R on keratinocytes, suppressing NF-κB-mediated inflammatory cytokines at the skin level. Topical KPV has shown promise in animal models of psoriasis and is now entering clinical use as a compounded preparation.

Pillar 5: Adjunct Therapies

Ozone Therapy

Systemic ozone delivered via Major Autohemotherapy (MAH) — 100–200 mcg/mL ozone in 100–200 mL blood — produces an immunological hormetic response: transient oxidative stress followed by upregulation of endogenous antioxidant systems (Nrf2/HO-1) and regulatory cytokine profiles. In psoriasis, ozone’s net effect is anti-inflammatory and immune-normalising. Small European studies report improvements in PASI and DLQI scores after 10–15 MAH sessions. Ozone also reduces bacterial translocation by improving gut barrier function and has antifungal activity relevant to Candida-driven psoriasis flares.

Stress and HPA Axis Regulation

Psychological stress is a well-documented psoriasis trigger, operating through the CRH-mast cell-neurogenic inflammation axis. The neuropeptide CRH, released from skin nerve fibres during stress, activates mast cells adjacent to keratinocytes and amplifies the IL-31/IL-33 itch-scratch-inflammation cycle.

Interventions with evidence:

• Mindfulness-Based Stress Reduction (MBSR): RCTs demonstrate faster psoriasis clearance during phototherapy when combined with MBSR
• Ashwagandha: cortisol reduction, HPA axis normalisation — see Ashwagandha for Cortisol and Stress
• Phosphatidylserine: 300–600 mg/day blunts cortisol response to psychological stressors

Monitoring and Titration

PASI and DLQI Tracking

Use the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) at baseline and every 4 weeks. These are standardised, reproducible, and allow meaningful comparison to biologic trial benchmarks (PASI-75 = 75% reduction = minimum acceptable response in trials).

Lab Re-Testing Schedule

If PASI does not improve ≥50% at 12 weeks despite full protocol adherence, add thymosin alpha-1 if not already included, and consider Lyme serology re-evaluation (occult co-infection frequently maintains Th17 drive in refractory cases).

For patients whose psoriasis is accompanied by joint involvement, low dose naltrexone for psoriatic arthritis details the specific LDN dosing protocol, monitoring parameters, and DMARD combination strategies relevant to this subgroup.

Related Articles

• Low-Dose Naltrexone: Evidence Across Autoimmune Conditions
• Photobiomodulation: A Clinical Guide
• Thymosin Alpha-1: Dosage, Timing, and Immune Targets
• Quercetin as a Senolytic and Anti-Inflammatory Agent
• KPV Peptide: Anti-Inflammatory Applications in Gut and Skin

References

1. Lande R, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564-569. PMID: 17873860
2. Hewlings SJ, Kalman DS. Curcumin: A review of its effects on human health. Foods. 2017;6(10):92. PMID: 29065496
3. Menter A, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis. J Am Acad Dermatol. 2019;80(4):1029-1072. PMID: 30772097
4. Gisondi P, et al. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21-28. PMID: 29241756
5. Sikora M, et al. Gut microbiome in psoriasis: An updated review. Pathogens. 2020;9(6):463. PMID: 32532013
6. Smith MP, et al. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol. 2011;106(10):1847. PMID: 21931375
7. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337-361. PMID: 28748217